Please ensure Javascript is enabled for purposes of website accessibility

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

By Keith Speights - Jun 15, 2021 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The declines appear to be caused simply by volatility that's common with small biotech stocks.

What happened

Shares of several COVID-19 vaccine makers were sinking on Tuesday morning. Dynavax Technologies (DVAX -2.27%) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NVAX -5.56%) and Vaxart (VXRT -3.72%) were falling 7.8% and 10.6%, respectively.

None of these three companies announced any news today. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down.

So what

The best thing that investors can do when stocks fall for no apparent reason is... nothing. Instead, continue to focus on the prospects for the underlying businesses behind those stocks.

Healthcare professional holding a syringe with needle and a vaccine vial.

Image source: Getty Images.

Dynavax, for example, already has a product on the market. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic. However, Dynavax plans to launch the vaccine in Europe this year. It also has a strong growth driver on its hands with the CpG 1019 adjuvant. 

Novavax just announced overwhelmingly positive results from a late-stage study conducted in the U.S. and Mexico for its COVID-19 vaccine, NVX-CoV2373. The experimental vaccine achieved an overall efficacy of 90.4% with 100% protection against moderate and severe COVID-19. 

Vaxart is evaluating its lead oral COVID-19 vaccine candidate in clinical testing with plans to advance a couple of variant-specific candidates into clinical studies this year. The company also has early-stage clinical studies under way for its oral norovirus vaccine.

Now what

Any or all of these three stocks could bounce back as quickly as they have fallen. Novavax appears to be in the strongest position with the company planning to file for regulatory authorizations of its COVID-19 vaccine in the third quarter of 2021. Dynavax and Vaxart also have potential catalysts on the way, though.

Dynavax is preparing to launch Heplisav-B in the European Union in the fourth quarter. Several of its partners expect to report clinical results for experimental COVID-19 vaccines using CpG 1018 as an adjuvant this year. Vaxart plans to advance its oral COVID-19 vaccine candidate into phase 2 testing within the next few months and begin phase 1/2 studies of its variant-specific candidates in the third quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$37.18 (-5.56%) $-2.19
Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$12.47 (-2.27%) $0.29
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$3.88 (-3.72%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.